Literature DB >> 6144475

Circulating lipid A antibodies despite absence of systemic endotoxemia in patients with Crohn's disease.

W Kruis, P Schussler, M Weinzierl, C Galanos, J Eisenburg.   

Abstract

Lipid A is a component common to endotoxins of gram-negative bacteria. It has been suggested that the gut wall of patients with inflammatory bowel disease is more permeable to luminal bacterial macromolecules which may stimulate the gut-associated lymphoid tissue. We therefore investigated 40 patients with Crohn's disease (CD) and 23 patients with ulcerative colitis (UC) with respect to their lipid A antibody titers and presence of endotoxins (Limulus test). Both tests were performed simultaneously using peripheral venous blood. Systemic endotoxin was demonstrated in only two of the patients. The lipid A antibody titers in the CD patients were significantly higher than either in patients with UC or in 42 healthy controls. Lipid A titers of patients with UC did not differ from those of controls. Titers of lipid A were significantly higher in patients with active Crohn's disease than in patients with inactive disease. It is concluded that systemic endotoxemia occurs rarely in patients with inflammatory bowel disease; however, despite this virtual absence of endotoxins in their peripheral blood, patients with CD show an increase in antibody formation against lipid A. This is suggestive of an altered immunologic reactivity against endotoxins in patients with CD and may be relevant to the pathogenesis of this disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6144475     DOI: 10.1007/bf01296269

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  46 in total

Review 1.  Bacterial endotoxins. The second Carl Prausnitz Memorial Lecture.

Authors:  O Westphal
Journal:  Int Arch Allergy Appl Immunol       Date:  1975

Review 2.  Biology of endotoxin.

Authors:  R J Elin; S M Wolff
Journal:  Annu Rev Med       Date:  1976       Impact factor: 13.739

3.  Limitations of the usefulness of the Limulus assay for endotoxin.

Authors:  R J Stumacher; M J Kovnat; W R McCabe
Journal:  N Engl J Med       Date:  1973-06-14       Impact factor: 91.245

4.  Influence of liver-RES on toxic liver damage due to galactosamine.

Authors:  M Grün; H Liehr; W Grün; U Rasenack; D Brunswig
Journal:  Acta Hepatogastroenterol (Stuttg)       Date:  1974-02

5.  Cell wall-defective variants of pseudomonas-like (group Va) bacteria in Crohn's disease.

Authors:  K Parent; P Mitchell
Journal:  Gastroenterology       Date:  1978-09       Impact factor: 22.682

Review 6.  Aetiological theories of inflammatory bowel disease.

Authors:  D B Sachar; M O Auslander; J S Walfish
Journal:  Clin Gastroenterol       Date:  1980-05

7.  Antibodies to synthetic polyribonucleotides in spouses of patients with inflammatory bowel disease.

Authors:  R J DeHoratius; R G Strickland; W C Miller; N A Volpicelli; R F Gaeke; J B Kirsner; R C Williams
Journal:  Lancet       Date:  1978-05-27       Impact factor: 79.321

8.  Mucosal-associated bacterial flora of the intestine in patients with Crohn's disease and in a control group.

Authors:  S Peach; M R Lock; D Katz; I P Todd; S Tabaqchali
Journal:  Gut       Date:  1978-11       Impact factor: 23.059

9.  Studies on the intestinal flora. II. Bacterial flora of the small intestine in patients with gastrointestinal disorders.

Authors:  B S Drasar; M Shiner
Journal:  Gut       Date:  1969-10       Impact factor: 23.059

10.  Bacteriological and endotoxin studies in cases of ulcerative colitis submitted to surgery.

Authors:  K R Palmer; B I Duerden; C D Holdsworth
Journal:  Gut       Date:  1980-10       Impact factor: 23.059

View more
  14 in total

1.  Endotoxin inactivation in plasma from septic patients: an in vitro study.

Authors:  P Olofsson; C Olofsson; G Nylander; P Olsson
Journal:  World J Surg       Date:  1986-04       Impact factor: 3.352

2.  Absence of complement fixing antibodies against lipopolysaccharides from Escherichia coli in a subgroup of patients with Crohn's disease.

Authors:  M Zeitz; U Hope; B Wust; C Galanos; B Möller; T J Lawley; E O Riecken
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

3.  Evaluation of intestinal permeability in patients with inflammatory bowel disease using lactulose and measuring antibodies to lipid A.

Authors:  T Oriishi; M Sata; A Toyonaga; E Sasaki; K Tanikawa
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

Review 4.  New insights into the pathogenesis and treatment of necrotizing enterocolitis: Toll-like receptors and beyond.

Authors:  Amin Afrazi; Chhinder P Sodhi; Ward Richardson; Matthew Neal; Misty Good; Richard Siggers; David J Hackam
Journal:  Pediatr Res       Date:  2011-03       Impact factor: 3.756

5.  Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatory bowel disease.

Authors:  M E McAlindon; C J Hawkey; Y R Mahida
Journal:  Gut       Date:  1998-02       Impact factor: 23.059

Review 6.  Insights into virulence factors determining the pathogenicity of Cronobacter sakazakii.

Authors:  Niharika Singh; Gunjan Goel; Mamta Raghav
Journal:  Virulence       Date:  2015-05-07       Impact factor: 5.882

7.  Prolonged endotoxemia enhances the renal injuries induced by gentamicin in rats.

Authors:  P Auclair; D Tardif; D Beauchamp; P Gourde; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

8.  Endotoxaemia in active Crohn's disease. Treatment with whole gut irrigation and 5-aminosalicylic acid.

Authors:  W Wellmann; P C Fink; F Benner; F W Schmidt
Journal:  Gut       Date:  1986-07       Impact factor: 23.059

9.  Antibodies to Mycobacterium paratuberculosis and nine species of environmental mycobacteria in Crohn's disease and control subjects.

Authors:  K J Stainsby; J R Lowes; R N Allan; J P Ibbotson
Journal:  Gut       Date:  1993-03       Impact factor: 23.059

Review 10.  Crohn's disease and the mycobacterioses: a review and comparison of two disease entities.

Authors:  R J Chiodini
Journal:  Clin Microbiol Rev       Date:  1989-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.